Considering all the recent outcomes of neonatal respiratory care, Bronchopulmonary Dysplasia, or BPD, is still the most prevalent reason of serious morbidity in premature neonates. The neonate’s engagement in this process results in longer hospitalization, and in long term, difficulties in life. BPD is essentially a diagnosis based on pathologic findings, in which mechanical ventilation and oxygen contact in preterm lungs affiliated with RDS are among its most important pathogens. This disease is also known as Chronic Lung Disease or CLD. At present, CLD is defined with the need for supplementary oxygen for at least 28 days after birth. As the pathogens for CLD are multifactorial, approaches to this disease are focused on medical interventions and prevention. Due to the fact that the etymology of BPD involves mechanical ventilation, oxygen toxicity, infection processes, and inflammation as the core factors, a wide range of medicinal and non-medicinal approaches are introduced for its prevention and treatment. In the current study, an aerosol corticosteroid, namely Budesonide, is used to prevent BPD. The inclusion criteria involves neonates with less than 28 weeks of gestation, who are diagnosed with RDS and are treated with nCPAP and receive surfactant in the first two hours of birth. For the case group, administering aerosolized Budesonide starts at 12 hours after birth and continues each 12 hours for at least 7 days or as long as the neonate is under nCPAP.